-
-
-
-
-
-
-
Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market
-
-
-
-
-
-
-
Cadrenal Therapeutics (CVKD) Announces Collaboration Agreement with Abbott (ABT) in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD
-
-
-
-
-
-
-
Cadrenal Therapeutics (CVKD) will begin trading on split-adjusted basis on August 20
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

